Wendy Sanhai Joins ELIQUENT Life Sciences Board

Regulatory, quality, and safety consulting firm ELIQUENT Life Sciences has appointed Wendy Sanhai, Ph.D., to its Board of Directors.

“We are thrilled to welcome Dr. Sanhai to ELIQUENT’s Board of Directors,” ELIQUENT Life Sciences CEO Tim Dietlin said. “Her understanding of the scientific, clinical, and regulatory landscapes, paired with her strategic expertise at both the board and C-suite levels, will be a catalyst for sustainable growth and lasting impact.”

A life sciences leader and scientific expert, Dr. Sanhai’s professional background spans roles in academia, regulated industry, and senior positions at the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH). As the former senior scientific advisor in the Office of the FDA Commissioner, she spearheaded strategic initiatives to advance medical product development, bridge public health gaps, and improve patient care. During her tenure as director of Public-Private Partnerships at the Foundation for NIH, Dr. Sanhai led collaborations with industry and external stakeholders to further NIH’s mission of advancing research and improving health outcomes.

In private industry, Dr. Sanhai was senior director at GlaxoSmithKline, where she worked across therapeutic areas and international business units to accelerate drug development and achieve organizational objectives. Most recently, at Deloitte Consulting LLC, she advised senior leaders across NIH, FDA, the U.S. Department of Defense, the Veterans Health Administration, and multiple life sciences Fortune 500 companies in crafting solutions and driving operational efficiencies in public health, medical product development, and regulatory strategies.

Related: ELIQUENT Life Sciences Recruits Former FDA Senior Executives to its C-Suite

Dr. Sanhai currently serves as a board member of several organizations, including the Medicines for Malaria Ventures (MMV); University of Maryland Board of Trustees and the Advisory Board of the Robert H. Smith School of Business; and a member of the Burroughs Wellcome Fund Innovation in Regulatory Science, Advisory Committee. She is a Visiting Professor of Practice and Executive in Residence at the University of Maryland, Robert H. Smith School of Business, and an associate professor (adjunct) at Duke School of Medicine.

Dr. Sanhai earned her Ph.D. in clinical biochemistry from the State University of New York at Buffalo, an MBA from the University of Maryland, and a bachelor of science degree from the University of Florida.

ELIQUENT redefines regulatory consulting with a full-service platform that delivers integrated solutions across the product lifecycle. The firm’s assembly of regulatory leaders, industry experts, and technical specialists collaborate seamlessly to advise clients on the complex process of bringing new therapies to market and manufacturing them to quality standards. ELIQUENT’s platform of regulatory service offerings feature Regulatory Affairs Solutions, Pharmacovigilance & Risk Management Solutions, Quality & Compliance Solutions, Remediations Solutions., and Talent Solutions.

ELIQUENT Life Sciences was established by uniting the expertise of six premier consultancies — Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, RApport Global, and IDEC — into a single, globally integrated organization. THE ELIQUENT team works cross-functionally to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to gain and maintain product authorization. ELIQUENT’s services support innovators across therapeutic modalities, phase-based pathways, and major global markets. ELIQUENT’s growth is supported by GHO Capital, the European specialist healthcare investor.